Bruno Terra Correa, Gabriela Sales Serra Silva, Webert Joaquim Silva Mendes, Laryssa Lopes Soares, Joice Antunes Lima, Catarina Graziela Sousa Pereira, João Vitor Torquato de Souza, M. Cassiano dos Santos, Augusto Cezar Magalhães Aleluia, Caroline Conceição da Guarda, Regiana Quinto Souza Póvoas, Marilda de Souza Gonçalves, Milena Magalhães Aleluia
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, representing a major global health concern, particularly in developing countries. This review provides an updated overview of the epidemiology, diagnosis, prognosis, treatment, and a Brazilian perspective for ALL. Despite advances in chemotherapy and immunotherapy, survival disparities remain challenging, driven by socioeconomic and healthcare access inequalities. Present diagnosis incorporates immunophenotyping, cytogenetics, and molecular biology for precise stratification and treatment planning. Treatment has evolved from monotherapy to multi-phase chemotherapy protocols, hematopoietic stem cell transplantation, monoclonal antibodies, and CAR T-cell therapy with risk-adapted strategies improving outcomes and offering hope in relapsed or refractory cases. However, these treatments remain largely inaccessible in low-to middle-income countries. Our review summarizes findings from Brazilian studies in children with ALL about diagnostics and treatment and highlights the importance of an accurate understanding of the national reality. Improved access to diagnostics, novel therapies, local multi-center studies, and pharmaceutical investment to enhance survival and quality of life for pediatric ALL patients is needed.